Takeda Pharmaceuticals??'s Investigational, Oral Proteasome Inhibitor ...

Takeda Pharmaceuticals 's Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis Takeda's Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic Light-chain Amyloidosis First proteasome inhibitor and first investigational therapy for amyloidosis to receive FDA Breakthrough Therapy designation CAMBRIDGE, Mass.

http://ift.tt/1vKF7s4